Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on assets-61%+24.6pp-85.6%-32.0pp-53.6%-4.4pp-49.2%
Liquidity
Current ratio6.5×+2.5×3.9×-0.6×4.5×-0.5×-0.1×5.1×+1.2×
Quick ratio6.5×+2.5×3.9×-0.6×4.5×-0.5×-0.1×5.1×+1.2×
Cash ratio6.1×+2.4×3.7×-0.6×4.3×-0.5×4.8×-0.2×+1.2×
Leverage
Debt-to-assets+0.3×0.7×+0.1×0.6×+0.1×0.5×+0.1×0.4×+0.4×
Interest coverage-9.5×+1.6×-11.1×+6.0×-17.1×+11.6×-28.6×+8.7×-37.3×-12.8×
Per Share
Book value per share-$1.35-362%$0.52-78.3%$2.38-46.3%$4.43-27.4%$6.11-31.5%
Valuation
Market capitalization$1.4B+546%$1.15B+136%$487.87M+128%$213.66M+5.5%$202.52M-9.2%
Enterprise value$1.42B+1,233%$1.13B+156%$441.69M+230%$133.89M+44.7%$92.53M+18.0%
Free cash flow yield-9.5%+68.6pp-11.3%+18.1pp-29.4%+36.2pp-65.6%+17.7pp-83.3%+5.0pp
Earnings yield-9.3%-829pp-12.2%+9.8pp-22%+32.2pp-54.2%-929pp874.4%+95.9pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Inhibrx Biosciences, Inc.'s ratios come from?
Every ratio is computed from Inhibrx Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.